Research programme: drug discovery - Bayer/Vipergen
Latest Information Update: 18 Jul 2016
At a glance
- Originator Vipergen ApS
- Developer Bayer; Vipergen ApS
- Class Small molecules
- Mechanism of Action Protein modulators; Protein-protein interaction modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 17 Jul 2015 Early research in Undefined indication in Denmark (unspecified route)